Latest Articles

Publication Date
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.
Impact of Positive Peritoneal Cytology on Prognosis in Stage IA Endometrial Cancer: A Retrospective Cohort Study in the Era of Minimally Invasive Surgery - Cureus

Impact of Positive Peritoneal Cytology on Prognosis in Stage IA Endometrial Cancer: A Retrospective Cohort Study in the Era of Minimally Invasive Surgery Cureus

Published: April 17, 2025, 11:08 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.
The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer - Nature

The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer Nature

Published: April 17, 2025, 12:18 p.m.
Factors Influencing Sentinel Node Mapping Failure in Endometrial Cancer - Physician's Weekly

Factors Influencing Sentinel Node Mapping Failure in Endometrial Cancer Physician's Weekly

Published: April 17, 2025, 10:41 a.m.
Role of Lymphadenectomy in the Management of Early-Stage Endometrial Cancer - Cureus

Role of Lymphadenectomy in the Management of Early-Stage Endometrial Cancer Cureus

Published: April 17, 2025, 6:27 a.m.
Efficacy and Safety of Robotic Surgery With Sentinel Lymph Node Navigation in Obese Patients With Endometrial Cancer: A Retrospective Study - Cureus

Efficacy and Safety of Robotic Surgery With Sentinel Lymph Node Navigation in Obese Patients With Endometrial Cancer: A Retrospective Study Cureus

Published: April 16, 2025, 6:31 a.m.
Endometrial histological patterns and associated factors of abnormal uterine bleeding among women seeking gynecological services from referral hospitals in Western Uganda: a cross-sectional study - BMC Women's Health

Endometrial histological patterns and associated factors of abnormal uterine bleeding among women seeking gynecological services from referral hospitals in Western Uganda: a cross-sectional study BMC Women's Health

Published: April 16, 2025, 3:54 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!